Plain-English translation of NCT07666490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a newer inhaler called Trimbow (which contains three active ingredients) works better than a commonly used inhaler called Foster (which contains two active ingredients) for people whose asthma is not well controlled. Both inhalers are breathed in twice a day. The study will follow 644 adults to see which medication better controls their asthma symptoms and prevents flare-ups.
Even when people take asthma medications regularly, some still struggle with poor symptom control and frequent flare-ups. This study wants to see if adding a third ingredient to the inhaler can help patients achieve better asthma control than the current standard two-ingredient treatment.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to use one of two inhalers twice daily for the duration of the study. You would use a smartphone app to answer questions about your asthma symptoms and track how well your symptoms are controlled. You would visit the clinic at multiple timepoints so researchers can check your asthma control, monitor for any side effects, and collect information about how often you experience asthma flare-ups.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Bulgaria